<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598129</url>
  </required_header>
  <id_info>
    <org_study_id>Oncos-C1</org_study_id>
    <nct_id>NCT01598129</nct_id>
  </id_info>
  <brief_title>ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers</brief_title>
  <official_title>Exploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targovax Oy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targovax ASA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and the recommended dose for later use
      of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the
      treatment of advanced cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CGTG-102 is an adenovirus that has been armed with granulocyte-macrophage colony stimulating
      factor (GMCSF), a potent stimulator of immunological cells.

      With regard to oncolytic viruses, replication in normal cells does not take place, and
      therefore viruses such as CGTG-102 are not known to cause any disease. Further, to date there
      has been no incidence of passing the virus on to other humans from patients. Since the virus
      requires tumor cells to multiply, such events are unlikely.

      To this day more than 100 patients have been treated with CGTG-102. This clinical trial will
      take place over approximately 6 months. The study includes 12 visits to the hospital, 1
      screening visit, 9 injection visits including overnight stay at the hospital(performed on
      trial days 1, 4, 8, 15, 29, 57, 85, 113 and 141), 1 end of treatment visit (day 169) and 1
      end of study visit (day 190). Oral treatment with cyclophosphamide (1 pill per day) will
      start on the day after the first injection and last until visit day 169.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose by Identification of Any Dose Limiting Toxicities</measure>
    <time_frame>6 months</time_frame>
    <description>No Dose Limiting Toxicities were observed at any dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Safety, Tolerability and Adverse Event Profile of CGTG-102 With Low-dose CPO. To Obtain Preliminary Evidence of Antitumour Activity.</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical and laboratory assessment. Response rate, disease control rate, progression free and overall survival.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Stable Disease Status as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Evaluation Three Months After Starting CGTG-102 Treatment.</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Using EORTC QLQ-C30.</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the feasibility and usefulness of EORTC QLQ-C30 for possible use in later studies.</description>
  </other_outcome>
  <other_outcome>
    <measure>An Immune Response to Treatment Was Assessed by Measuring a Temporary Increase in Pro-inflammatory Cytokines After Treatment Was Administrered.</measure>
    <time_frame>6 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Infiltration of CD8+ T Cells Into Tumors.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Induction of Tumor-specific CD8+ T Cells in Peripheral Blood Monomuclear Cells.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Malignant Solid Tumour</condition>
  <arm_group>
    <arm_group_label>CGTG-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CGTG-102 dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ONCOS-102</intervention_name>
    <description>GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
    <arm_group_label>CGTG-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Solid tumour refractory to evidence-based oncological therapies.

          2. Age 18 years and over.

          3. At least one tumour mass measurable by PET (i.e. PET-positive lesion that can reliably
             be assessed for SUVmax, typically featuring longest diameter ≥2 cm).

          4. Tumour is injectable i.t. by direct visualisation/palpation or by imaging-guidance
             (ultrasound). I.t. includes intracavitary injections, particularly intraperitoneal and
             intrapleural.

          5. Histological confirmation of primary disease or relapse.

          6. Patient has given signed informed consent.

          7. WHO performance score 0-1 and life expectancy more than 3 months.

          8. Previous anti-cancer treatment at least 1 month before Day 1.

          9. Tumour assessed to be suitable for biopsy.

         10. Hepatic, renal and bone marrow functions within normal limits for the target
             population as indicated by the following:

               -  Total bilirubin ≤ the upper limit of normal (ULN).

               -  ASAT, ALAT ≤3.0 × ULN.

               -  Serum creatinine ≤1.5 x ULN.

               -  International normalised ratio (INR) ≤1.5 x ULN.

               -  Haematologic parameters: Patients can be transfused to meet the haemoglobin and
                  platelet count entry criteria.

                    -  Haemoglobin ≥10 g/dL

                    -  Leucocytes ≥2.3 x 109/L

                    -  Platelet count ≥7.5 x 109/L

        Exclusion Criteria:

          1. Use of high dose systemic immune suppressive medication within 3 weeks of anticipated
             first treatment. Note: patients taking low-dose corticosteroids for the treatment of
             nausea and/or taking maintenance corticosteroids are permitted to enrol.

          2. Known infection with HIV or known underlying genetic immunodeficiency disease as these
             might affect the safety and efficacy of treatment.

          3. Treatment of the injected tumour(s) with radiotherapy, chemotherapy, surgery, or an
             investigational drug within 4 weeks prior to the first treatment.

          4. Recent thromboembolic event (deep venous thrombosis, pulmonary embolism).

          5. Clinically significant active infection or clinically significant medical condition
             considered high risk for investigational new drug treatment (e.g. pulmonary,
             neurological, cardiovascular, metabolic, clinically significant and/or rapidly
             accumulating pericardial effusion).

          6. Severe or unstable cardiac disease.

          7. Known brain metastases, glioma. Central nervous system malignancy, including
             carcinomatosis meningitis.

          8. Pulse oximetry oxygen saturation &lt;90% at rest in room air.

          9. Vaccination with a live virus (i.e. measles, mumps, rubella, etc.) &lt;30 days prior to
             the first treatment.

         10. History of hepatic dysfunction, cirrhosis or hepatitis.

         11. Prior organ transplant.

         12. Pregnant or lactating patients.

         13. Evidence of coagulation disorder.

         14. Other conditions which, in the opinion of the investigator, might interfere with the
             study findings or represent a safety hazard for the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikael von Euler, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Oncos Therapeutics Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Docrates Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2012</study_first_posted>
  <results_first_submitted>June 11, 2014</results_first_submitted>
  <results_first_submitted_qc>October 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2014</results_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>oncolytic virus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CGTG-102</title>
          <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deterioration of WHO status to WHO 4</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CGTG-102</title>
          <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="38" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of cancer indications</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability.</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGTG-102</title>
            <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any (Serious and Non-Serious) Adverse Event Measured to Assess Safety and Tolerability.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Safety, Tolerability and Adverse Event Profile of CGTG-102 With Low-dose CPO. To Obtain Preliminary Evidence of Antitumour Activity.</title>
        <description>Clinical and laboratory assessment. Response rate, disease control rate, progression free and overall survival.</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Stable Disease Status as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Evaluation Three Months After Starting CGTG-102 Treatment.</title>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGTG-102</title>
            <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable Disease Status as Defined by Response Evaluation Criteria In Solid Tumors (RECIST) Evaluation Three Months After Starting CGTG-102 Treatment.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Using EORTC QLQ-C30.</title>
        <description>To assess the feasibility and usefulness of EORTC QLQ-C30 for possible use in later studies.</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>An Immune Response to Treatment Was Assessed by Measuring a Temporary Increase in Pro-inflammatory Cytokines After Treatment Was Administrered.</title>
        <time_frame>6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGTG-102</title>
            <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>An Immune Response to Treatment Was Assessed by Measuring a Temporary Increase in Pro-inflammatory Cytokines After Treatment Was Administrered.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Infiltration of CD8+ T Cells Into Tumors.</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGTG-102</title>
            <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Infiltration of CD8+ T Cells Into Tumors.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Induction of Tumor-specific CD8+ T Cells in Peripheral Blood Monomuclear Cells.</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGTG-102</title>
            <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Induction of Tumor-specific CD8+ T Cells in Peripheral Blood Monomuclear Cells.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase 2 Dose by Identification of Any Dose Limiting Toxicities</title>
        <description>No Dose Limiting Toxicities were observed at any dose level.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CGTG-102</title>
            <description>CGTG-102 dose escalation
ONCOS-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase 2 Dose by Identification of Any Dose Limiting Toxicities</title>
          <description>No Dose Limiting Toxicities were observed at any dose level.</description>
          <units>Dose limiting toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed up for Adverse Events throughout the study.</time_frame>
      <desc>There was no indication of a relationship between dose of CGTG-102 and the incidence or intensity of Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>CGTG-102</title>
          <description>CGTG-102 dose escalation
CGTG-102: GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal obstruction and small intestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia and peripheral oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Operations</name_or_title>
      <organization>Oncos Therapeutics</organization>
      <email>info@oncos.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

